

## BIOADVANCE HEADLINES

**BioAdvance Closes \$26 Million Early Stage Fund:** BioAdvance Ventures, sponsored by BioAdvance and managed by Quaker BioVentures, is the first dedicated early stage fund for life sciences companies in Pennsylvania. Investors include Cephalon, GlaxoSmithKline/S.R. One, Merck, Synthes, Wyeth, Drexel University, Fox Chase Cancer Center, Thomas Jefferson University, University of the Sciences in Philadelphia, The Wistar Institute, Aqua America, Ben Franklin Technology Partners, Independence Blue Cross Pension Trust, the Delaware River Port Authority and Montgomery County Employees Retirement System. [See more at www.bioadvance.com](http://www.bioadvance.com)

**BioAdvance Opens Third Funding Round:** BioAdvance launched its third funding cycle for early-stage, southeastern PA-based life science technologies and has received 42 registrations which are now under review. Selected innovators will be announced in early 2005. Through its Greenhouse Fund, BioAdvance has received 185 total registrations from its three cumulative funding rounds, and has selected 18 projects to date for \$5.7M in total committed funds. [See more at www.bioadvance.com](http://www.bioadvance.com)

**BioAdvance Ranked in Top 10 by Entrepreneur Magazine:** The publication named BioAdvance as a leader in its list of "Top 100 Venture Capital Firms for Entrepreneurs." [See more at www.entrepreneur.com](http://www.entrepreneur.com)

**BioAdvance Supports Workforce Training through Greater Philadelphia Bioinformatics Alliance:** GPBA, a consortium of eight regional universities and research institutions, held an in-depth short-course series and several workshops in Functional Genomics attracting dozens of regional students and professionals. GPBA also hosted its 2nd annual full-day retreat at Penn State Great Valley on October 15th. [See more at www.gpba-retreat.pcbi.upenn.edu](http://www.gpba-retreat.pcbi.upenn.edu) or [www.bioadvance.com](http://www.bioadvance.com)

## COMPANY CORNER

**Acuity Pharmaceuticals Raises \$15M in Funding.** Acuity, of Philadelphia, closed its \$15 million Series B financing. The new funding enabled the company to initiate the first-ever human clinical trial for a therapy using RNA interference, a pioneering new technology that shuts down disease-causing genes. Acuity's drug is for the treatment for macular degeneration, the leading cause of adult blindness, and uses technology exclusively licensed from the University of Pennsylvania. Acuity received \$500,000 funding from BioAdvance earlier this year. [See more at www.bioadvance.com](http://www.bioadvance.com) or [www.acuitypharma.com](http://www.acuitypharma.com)

**PhenoTech, Inc. Develops Novel Blood Typing Reagents.** PhenoTech, of Philadelphia, uses its proprietary technologies licensed from University of Pennsylvania to rapidly develop unique monoclonal antibodies with diagnostic and therapeutic applications. PhenoTech develops an important new generation of blood typing reagents, bringing blood cell typing into the 21st century with a faster, easier and more comprehensive alternative to current 50 year old reagent technology. PhenoTech received its initial funding from BioAdvance and has also received a grant from the NIH to pursue its research in blood typing. [See more at www.bioadvance.com](http://www.bioadvance.com)

**Protez Pharmaceuticals Uses BioAdvance Funding to Complete Chemistry and Biology Staffing.** Protez, of Malvern, develops new antibiotics for difficult-to-treat infections in the hospital. The company is advancing three novel programs and is building its core biology, chemistry, and management teams in southeastern Pennsylvania. [See more at www.bioadvance.com](http://www.bioadvance.com) or [www.protez.com](http://www.protez.com)

**RetinaPharma Technologies, Inc.'s TonoPach™ (developed with support from BioAdvance), has Planned Market Introduction in 2005.** RetinaPharma, of Jenkintown, used BioAdvance funding to complete the commercial prototype of a new device to more accurately detect glaucoma. Worldwide an estimated 66.8 million people have visual impairment from glaucoma, with 6.7 million suffering from blindness. [See more at www.bioadvance.com](http://www.bioadvance.com) or [www.retinapharma.com](http://www.retinapharma.com)

**Yaupon Pharmaceuticals Advances Anti-Addiction Drug to Human Trials.** Yaupon, of Radnor, advanced Lobeline (for methamphetamine addiction) into Phase I human trials. Progress has been partially funded by BioAdvance, with a \$500,000 investment and in partnership with the National Institute of Drug Abuse. According to NIDA/NIH, "The abuse of methamphetamine – a potent psycho stimulant – is an extremely serious and growing national problem." [See more at www.bioadvance.com](http://www.bioadvance.com) or [www.yaupontherapeutics.com](http://www.yaupontherapeutics.com)

## MANAGEMENT

Barbara S. Schilberg  
Managing Director & CEO

Gary J. Kurtzman, M.D.  
Managing Director & COO

## BOARD MEMBERS

Frank Baldino, Jr. Ph.D. (Chairman)  
Chairman & CEO Cephalon, Inc.

Robert L. Barchi, M.D., Ph.D. (Vice Chairman)  
President, Thomas Jefferson University

Paul C. Brucker, M.D.  
President Emeritus, Thomas Jefferson University

Martin S. Dorph  
Vice President, CFO/Treasurer and Human  
Resource Administration, Temple University

Brenda Gavin, DVM  
Partner, Quaker BioVentures, L.P.

Phillip P. Gerbino, PharmD.  
President, University of the Sciences

Russel E. Kaufman, M.D.  
President & CEO, The Wistar Institute

Samuel P. Katz  
Partner/CEO, WellSpring BioCapital Partners

Barbara S. Schilberg  
Managing Director & CEO, BioAdvance

Mark S. Schweiker  
President & CEO, Greater Philadelphia  
Chamber of Commerce

Manuel Stamatakis  
CEO, Capital Management Enterprises

David U'Prichard, Ph.D.  
President, Druid Consulting LLC and Venture  
Partner, Apax Partners Ltd.

Tadataka Yamada, M.D.  
Chairman, R&D, Glaxo SmithKline

## EX OFFICIO MEMBERS

Dennis Yablonsky  
Secretary of Community and Economic  
Development, PA  
Department of Community and  
Economic Development

Calvin B. Johnson, M.D., M.P.H.  
Secretary of Health, PA Department of Health

## BOARD MEMBERS IN THE NEWS

**Frank Baldino, Jr. Ph.D. Featured in August PharmaVoice** BioAdvance Board chairman Dr. Baldino was prominently featured in the August issue of PharmaVoice Magazine ("A Man for All Seasons"). In the seven-page feature article, he discusses his role as Chairman, CEO and Founder of Cephalon and details his role in creating one of the world's fastest growing biotech companies. The article also discusses Dr. Baldino's leadership philosophy and his "above and beyond" activities including serving as chairman of BioAdvance's Board. [For article information visit www.pharmavoices.com](http://www.pharmavoices.com)

**Robert L. Barchi, M.D., Ph.D. Elected Jefferson's 4th President.** Dr. Barchi was inducted as Thomas Jefferson University's fourth president on October 5th during a ceremony at the Kimmel Center for the Performing Arts. Dr. Barchi succeeds university president Paul C. Brucker, M.D. who retired in July 2003 after a distinguished tenure of 14 years. Dr. Brucker is also a BioAdvance board member. [See more at www.jefferson.edu](http://www.jefferson.edu)

## BIOADVANCE WELCOMES NEW BOARD MEMBERS

**Russel E. Kaufman, M.D.,** Wistar President Joins BioAdvance Board. Dr. Kaufman, President & CEO, The Wistar Institute, joined the BioAdvance Board. In addition to his administrative duties, Dr. Kaufman maintains an active research program at the institute, investigating the genetics of blood diseases and cancer. [Read more at www.wistar.upenn.edu](http://www.wistar.upenn.edu)

**David U'Prichard, Ph.D.,** Pharmaceutical Veteran, and Entrepreneur-Turned-VC Joins BioAdvance Board. Dr. U'Prichard, the President of Druid Consulting LLC and a Venture Partner at Apax Partners Limited, joined the BioAdvance Board. From 1999 to 2003 he was CEO of 3-Dimensional Pharmaceuticals, Inc. Prior to that, Dr. U'Prichard worked with SmithKline Beecham, ICI/Zeneca and Nova Pharmaceuticals.

[See more at www.apax.com](http://www.apax.com)



Biotechnology Greenhouse of Southeastern Pennsylvania

*Accelerating the Business of Life Science*

3701 Market Street  
Philadelphia, PA 19104  
p: 215.966.6214  
f: 215.966.6215  
[www.bioadvance.com](http://www.bioadvance.com)